ATyr Pharma Stock Sinks, Plans FDA Review After Mixed Phase 3 Results

aTyr Pharma's stock fell over 81% following failed Phase 3 trial results. Trial for efzofitimod missed its primary endpoint, prompting investor sell-off. FDA engagement planned to explore regulatory options for efzofitimod. Some secondary endpoints showed promising results, despite primary miss. Stock currently priced at $1.06 with high session volume.

aTyr Pharma's lung disease drug misses main goal in late-stage trial

aTyr Pharma's drug missed primary endpoint in late-stage pulmonary sarcoidosis trial. Failure may impact investor confidence and future funding.

ATYR

ATYR price chart

ATyr Pharma Stock Sinks, Plans FDA Review After Mixed Phase 3 Results

aTyr Pharma's lung disease drug misses main goal in late-stage trial

Company intelligence